Skip to main content
. 2018 Jan 3;13(1):e0189765. doi: 10.1371/journal.pone.0189765

Fig 2. Common characteristics of studies.

Fig 2

Depicted are the number of studies sharing included cost elements (a), analyses incorporating TNF-inhibitors (b) and studies integrating ustekinumab, secukinumab and apremilast, which were approved more recently (c). AE: adverse events; Hosp: hospitalization.